REVIEW PAPER
Hashimoto’s disease as a risk factor for developing papillary thyroid cancer
1
Collegium Medicum w Bydgoszczy, UMK w Toruniu Wydział Lekarski, Polska
Med Og Nauk Zdr. 2019;25(1):12-15
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Already in 1955, Hashimoto disease, which is the most common autoimmune disease, was associated with the most common thyroid cancer – papillary thyroid cancer (PTC). Despite the passage of years and many intensive scientific studies on the relationship between these two diseases, the mechanism and the basis on which Hashimoto’s disease predisposes to PTC has still not been established.
Objective:
The aim of the study is to summarize the current state of knowledge on mechanisms by which HT may predispose to the development of PTC, and present the latest clinical trials confirming that HT is a risk factor for PTC, and describe its possible impact on the course of the disease.
Brief description of the state of knowledge:
The study concerns the inflammatory, immunological and genetic mechanisms that may be significantly related to the predisposition of HT patients to the development of PTC. Recent studies have shown that the RET / PTC oncogene or p63 protein can combine HT with PTC development. This study also presents the results of clinical trials regarding the comparison of the prevalence of PTC in patients with HT, and in patients without autoimmune thyroid disease.
Summary.:
There is a need for further scientific research through which more will be leant about the mechanisms linking HT and PTC. Vigilance should be maintained while caring for a patient with HT, as many scientific studies confirm the more frequent occurrence of PTC in patients afflicted with autoimmune thyroiditis. HT can also have a significant impact on the course of cancer and its prognosis.
Already in 1955, Hashimoto disease, which is the most common autoimmune disease, was associated with the most common thyroid cancer – papillary thyroid cancer (PTC). Despite the passage of years and many intensive scientific studies on the relationship between these two diseases, the mechanism and the basis on which Hashimoto’s disease predisposes to PTC has still not been established.
Objective:
The aim of the study is to summarize the current state of knowledge on mechanisms by which HT may predispose to the development of PTC, and present the latest clinical trials confirming that HT is a risk factor for PTC, and describe its possible impact on the course of the disease.
Brief description of the state of knowledge:
The study concerns the inflammatory, immunological and genetic mechanisms that may be significantly related to the predisposition of HT patients to the development of PTC. Recent studies have shown that the RET / PTC oncogene or p63 protein can combine HT with PTC development. This study also presents the results of clinical trials regarding the comparison of the prevalence of PTC in patients with HT, and in patients without autoimmune thyroid disease.
Summary.:
There is a need for further scientific research through which more will be leant about the mechanisms linking HT and PTC. Vigilance should be maintained while caring for a patient with HT, as many scientific studies confirm the more frequent occurrence of PTC in patients afflicted with autoimmune thyroiditis. HT can also have a significant impact on the course of cancer and its prognosis.
REFERENCES (30)
1.
Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017. Volume 390. Issue 10101; 1550–1562. doi: 10.1016/S0140- 6736(17)30703-1.
2.
Latina A, Gullo D, Trimarchi F, Benvenga S. Hashimoto’s thyroiditis: similar and dissimilar characteristics in neighboring areas. Possible implications for the epidemiology of thyroid cancer PLoS ONE 2013. 8(3): e55450. doi: 10.1371/journal.pone.0055450.
3.
Caturegli P, De Remigis A, Chuang K, Dembele M, Iwama A, Iwama S. Hashimoto’s thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid 2013; 23: 142–150. doi: 10.1089/thy.2012.0554.
4.
Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009; 32: 31–239. doi: 10.1016/j. jaut.2009.02.007.
5.
Lal G, Clark OH. Textbook of endocrine surgery, Philadelphia: Saunders. 2005. Chronic Thyroiditis; pp. 38–40.
6.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA A Cancer J Clin. 2016; 66: 115–132. doi: 10.3322/caac.21338.
8.
Yuan J, Li J, Chen X, Lin X, Du J, Zhao G, Chen Z, Wu Z. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma. Bull. Canc. 2017; 104: 516–523. doi: 10.1016/j. bulcan.2017.03.005.
9.
Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955; 2: 291–7. 4.
11.
Di Pasquale M, Rothstein JL, Palazzo JP. Pathologic features of Hashimoto’s-associated papillary thyroid carcinomas. Hum Pathol. 2001 Jan; 32(1): 24–30.
12.
Jakubowski W, Trzebińska A, Słapa RZ. Atlas badań ultrasonograficznych tarczycy. Roztoczańska Szkoła Ultrasonografii, Warszawa 2010, wyd 1.
13.
Białek EJ, Jakubowski W. Obraz ultrasonograficzny w różnych chorobach tarczycy. W: Białek EJ, Jakubowski W, red. Diagnostyka ultrasonograficzna tarczycy, przytarczycy i węzłów chłonnych szyi. Wyd 1. Gdańsk: MAKmed; 2001: 68–73.
14.
Polska Grupa do spraw Nowotworów Endokrynologicznych. Diagnostyka i leczenie raka tarczycy – rekomendacje polskie. Endokrynologia Polska. Tom 61; 5: 2010.
15.
Jakubowski W, Trzebińska A, Słapa RZ. Atlas Badań ultrasonograficznych tarczycy. Roztoczańska Szkoła Ultrasonografii. Warszawa-Zamość 2010.
16.
Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY i wsp. Clinical relationship between Hashimoto’s thyroiditis and papillary thyroid cancer, Acta Oncol 2011; 50: 228–1234. doi: 10.3109/0284186X.2011.602109.
17.
Kashima K, Yokoyama S, Noguchi S, Mukarami N, Yamashita H, Watanabe S i wsp. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998; 8: 197–202. doi: 10.1089/ thy.1998.8.197.
18.
Nikiforova MN,Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008; 8: 83–95. doi:https://doi.org/10.1586/147371....
19.
Sheils OM, O’Leary JJ, Uhlmann V, Lüttich K, Sweeney EC. RET/PTC-1 activation in Hashimoto thyroiditis, J Surg Pathol, 2000; 8: 185–189. doi: 10.1177/106689690000800305.
20.
Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, Multhaupt H, Atkins JP, Rosen MR, Keane WM, Rothstein JL. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto’s thyroiditis. Laryngoscope, 1997; 107: 95–100.
21.
Arif S, Blanes A, Diaz-Cano SJ. Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathology. 2002; 41: 357– 362. doi: 10.1046/j.1365-2559.2002.01467.x.
22.
Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis: a pathobiologic link? Hum Pathol. 2003; 34: 764–769.
23.
Burstein DE, Nagi C, Wang BY, Unger P. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto’s thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis, Hum Pathol. 2004; 35: 465–473.
24.
Uhliarova B, Hajtman A. Hashimoto’s thyroiditis – an independent risk factor for papillary carcinoma, Braz J Otorhinolaryngol, 2018 Nov – Dec; 84(6): 729–735. doi: 10.1016/j.bjorl.2017.08.012.
25.
Zhang L, Li H, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y. The clinical features of papillary thyroid cancer in Hashimoto’s thyroiditis patients from an area with a high prevalence of Hashimoto’s disease. BMC Cancer. 2012; 12:610. doi:10.1186/1471- 2407-12-610.
26.
Konturek A, Barczynski M, Wierzchowski W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbecks Arch Surg. 2013; 3: 389–94. doi: 10.1007/s00423-012- 1021-x.
27.
Consorti F, Loponte M, Milazzo F, Potasso L, Antonaci A. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res. 2010; 3–4: 333–7. doi: 10.1159/000320954.
28.
Matesa-Anic D, Matesa N, Dabelic N, Kusic Z. Coexistence of papillary carcinoma and Hashimoto’s thyroiditis. Acta Clin Croat. 2009; 1: 9–12.
29.
Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid. 2010; 6: 601–6. doi: 10.1089/ thy.2009.0450.
30.
Isik S, Gokay F, Ozuguz U, Topaloglu O, Tutuncu Y, Berker D, Guler S. Comparison of the prevalence and sonographic features of thyroid nodules accompanying autoimmune thyroid diseases. Endokrynol Pol. 2010; 6: 658–64.
| eISSN: | 2084-4905 |
| ISSN: | 2083-4543 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
